Sangamo Therapeutics (Sangamo Therapeutics) Change In Receivables : $3.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Change In Receivables?

Sangamo Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $0.4 Mil. It means Sangamo Therapeutics's Accounts Receivable declined by $0.4 Mil from Sep. 2023 to Dec. 2023 .

Sangamo Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $3.1 Mil. It means Sangamo Therapeutics's Accounts Receivable declined by $3.1 Mil from Dec. 2022 to Dec. 2023 .

Sangamo Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sangamo Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 41.25.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sangamo Therapeutics's liquidation value for the three months ended in Dec. 2023 was $-0.7 Mil.

Sangamo Therapeutics Change In Receivables Historical Data

The historical data trend for Sangamo Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Change In Receivables Chart

Sangamo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-32.54

31.33

-0.10

1.89

3.15

Sangamo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.57	-3.58	4.11	2.19	0.43

Sangamo Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.1 Mil.

Sangamo Therapeutics (NAS:SGMO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sangamo Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.923	/	2.042	*	91
=	41.25

2. In Ben Graham's calculation of liquidation value, Sangamo Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Sangamo Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	81.002	-	82.433	+	0.75 * 0.923	+	0.5 * 0
=	-0.7

Sangamo Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GBY:Germany

Address

7000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Executives

Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney	director	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow	officer: SVP-Chief Development Officer	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker	director
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby	officer: SVP, Gen. Counsel & Secretary	7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb	officer: EVP & General Counsel	5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot	officer: SVP, Chief Scientific Officer	7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott	officer: SVP, Head of Development	7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier	officer: EVP, Technical Operations	7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung	officer: EVP Chief Business Officer	7000 MARINA BLVD, BRISBANE CA 94005